Search results
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
UK researchers have discovered that passing a weak electrical current between electrodes on a person’s scalp may lead to a reduction in frequency of the visual hallucinations experienced by some people living with sight loss.
Thank you to all those who completed our recent Sight Loss Survey – almost 700 of you took the time to share your experiences.
Tuesday 27 May, 7.00pm - 8.30pm - via Zoom - Are you aged 18 to 30 and living with an inherited retinal dystrophy? Then come and join us for our latest Young Adults online social catch up and meet our new group facilitator Martik Aghajanian.
The Dr Jessie Mole lecture was inaugurated on 10 December 2001, in recognition of Jessie's outstanding contribution to BRPS, then RP Fighting Blindness and now Retina UK.
Katerina joined the Retina UK team at the start of 2023 after hearing about the charity through her involvement in a research project at the University of Bath, where she works as an academic.
Dan found out he had retinitis pigmentosa in February 2022, but he feels it has been “on cards for years”. He said he had “an inkling something was up but never did anything about it: a typical guy I guess!”
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.
